Abingdon Health surges after launch of Covid-19 antibody self-test

Abingdon Health surged on Monday after launching a Covid-19 antibody self-test it manufactured with BioSure.

The new test, for which BioSure is the legal manufacturer, has been CE marked specifically for self-testing. It uses a fraction of a drop of finger-prick blood and gives results in 20 minutes.

This allows individuals to know and monitor their own antibody status pre-vaccination, post vaccination and following infection with the SARS-CoV-2 virus. Abingdon said it will be particularly useful as populations worldwide continue to be vaccinated to monitor the effectiveness of an individual's immunity status.

Chief executive officer Chris Yates said: "We are delighted that BioSure have launched their product and equally happy to be their manufacturing partner. For individuals to be able to monitor their own antibody status at home is a great step in the management of Covid-19.

"Our own AbC-19 assay will complement this product and we expect the AbC-19 to gain additional utility in semi-quantitative format as recently announced. BioSure also distributes our AbC-19 test which is CE marked for professional use."

At 1400 BST, Abingdon shares were up 58% at 46p.